Free Trial
NASDAQ:IMRX

Immuneering (IMRX) Stock Price, News & Analysis

Immuneering logo
$1.58 +0.08 (+5.00%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Immuneering Stock (NASDAQ:IMRX)

Key Stats

Today's Range
$1.51
$1.59
50-Day Range
$1.46
$2.15
52-Week Range
$1.00
$3.83
Volume
16,107 shs
Average Volume
2.36 million shs
Market Capitalization
$56.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
Consensus Rating
Hold

Company Overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Remove Ads

Immuneering Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

IMRX MarketRank™: 

Immuneering scored higher than 68% of companies evaluated by MarketBeat, and ranked 352nd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immuneering has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Immuneering has only been the subject of 2 research reports in the past 90 days.

  • Read more about Immuneering's stock forecast and price target.
  • Earnings Growth

    Earnings for Immuneering are expected to grow in the coming year, from ($1.86) to ($1.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immuneering is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immuneering is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immuneering has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Immuneering's valuation and earnings.
  • Percentage of Shares Shorted

    5.48% of the float of Immuneering has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuneering has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuneering has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Immuneering does not currently pay a dividend.

  • Dividend Growth

    Immuneering does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.48% of the float of Immuneering has been sold short.
  • Short Interest Ratio / Days to Cover

    Immuneering has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immuneering has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Immuneering has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Immuneering this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for IMRX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immuneering insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immuneering's insider trading history.
Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

IMRX Stock News Headlines

Short Interest in Immuneering Co. (NASDAQ:IMRX) Drops By 12.9%
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Chardan Capital Forecasts Immuneering FY2025 Earnings
See More Headlines

IMRX Stock Analysis - Frequently Asked Questions

Immuneering's stock was trading at $2.20 at the beginning of 2025. Since then, IMRX stock has decreased by 31.8% and is now trading at $1.50.
View the best growth stocks for 2025 here
.

Immuneering Co. (NASDAQ:IMRX) issued its earnings results on Thursday, March, 20th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.16.

Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immuneering investors own include Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD).

Company Calendar

Last Earnings
3/20/2025
Today
4/02/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMRX
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$13.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+693.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-53,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$320,000.00
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
0.51

Miscellaneous

Free Float
23,288,000
Market Cap
$56.52 million
Optionable
Not Optionable
Beta
-0.32
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:IMRX) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners